Sumesh Kachroo
Research Subjects
Sumesh Kachroo has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Christopher M. Black
Outcomes Research, Merck & Co., Inc., Rahway, NJ, United States
10 shared publications Axel Svedbom
ICON plc, Stockholm, Sweden
5 shared publicationsJohan Dalén
ICON plc, Stockholm, Sweden
4 shared publications- Ameur M. Manceur
Analysis Group, Inc., Montreal, Canada
2 shared publications Anirban Basu
University of Washington, The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, Seattle, WA 98195, USA
2 shared publications- Changxia Shao
Merck & Co., Inc., Rahway, NJ 07065, USA
2 shared publications
Latest Publications
- 9 July 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (10) , 4529-4545
Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare Resource Utilization in the United States: Findings from an Administrative Claims Database
Introduction Inflammatory bowel disease (IBD) is a chronic, immune-mediated gastrointestinal disorder comprised of Crohn's disease (CD) and ulcerative colitis (UC). Real-world data on racial differences in disease burden, treatment patterns, and healthcare resource utilization (HCRU) remain limited. Methods The retrospective observational study was conducted using Optum’s de-identified Clinformatics® Data Mart Database (Optum® CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity. Results A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals. Conclusion The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.
- 9 July 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (10) , 4529-4545
Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare Resource Utilization in the United States: Findings from an Administrative Claims Database
Introduction Inflammatory bowel disease (IBD) is a chronic, immune-mediated gastrointestinal disorder comprised of Crohn's disease (CD) and ulcerative colitis (UC). Real-world data on racial differences in disease burden, treatment patterns, and healthcare resource utilization (HCRU) remain limited. Methods The retrospective observational study was conducted using Optum’s de-identified Clinformatics® Data Mart Database (Optum® CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity. Results A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals. Conclusion The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Sa1568: PERSISTENCE AND OTHER TREATMENT PATTERNS AMONG BIOEXPERIENCED PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB OR ADALIMUMAB
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Sa1568: PERSISTENCE AND OTHER TREATMENT PATTERNS AMONG BIOEXPERIENCED PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB OR ADALIMUMAB
- 1 July 2021
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 10 (10) , 857-868
Clinical and utilization outcomes associated with tumor mutational burden in a real-world pan-tumor population
Aim & methods: This real-world study examined the association of tumor mutational burden (TMB) with clinical and healthcare utilization in adults diagnosed with advanced solid tumor 1 January 2015– 31 January 2019. Results: There were 170 patients in low-TMB group (TMBConclusion: Despite the limited sample, these data provide a historical perspective for examining real-world outcomes associated with TMB.
- 1 July 2021
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 10 (10) , 857-868
Clinical and utilization outcomes associated with tumor mutational burden in a real-world pan-tumor population
Aim & methods: This real-world study examined the association of tumor mutational burden (TMB) with clinical and healthcare utilization in adults diagnosed with advanced solid tumor 1 January 2015– 31 January 2019. Results: There were 170 patients in low-TMB group (TMBConclusion: Despite the limited sample, these data provide a historical perspective for examining real-world outcomes associated with TMB.
- 29 January 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (15) , 1879-1887
Real-World Patterns on Tumor Mutation Burden Testing in a Pan-Tumor Population
Background: There is limited real-world information on use of tumor mutational burden (TMB) testing and characteristics of patients receiving it. Materials & methods: Patients ≥18 years old and dia... Lay abstract There is limited real-world information on the use of tumor mutational burden (TMB) testing and the characteristics of patients who are receiving it. TMB is the total number of mutatio...
- 29 January 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (15) , 1879-1887
Real-World Patterns on Tumor Mutation Burden Testing in a Pan-Tumor Population
Background: There is limited real-world information on use of tumor mutational burden (TMB) testing and characteristics of patients receiving it. Materials & methods: Patients ≥18 years old and dia... Lay abstract There is limited real-world information on the use of tumor mutational burden (TMB) testing and the characteristics of patients who are receiving it. TMB is the total number of mutatio...
- 10 December 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (4) , 443-453
Clinical Effectiveness Outcomes and Healthcare Resource Utilization of Patients Diagnosed with Small-Cell Lung Cancer
Background: Real-world data are lacking on patients with small-cell lung cancer (SCLC) with extensive-stage SCLC (eSCLC) and poor performance status (PS). Patients & methods: Eligible patients diag... Lay abstract Real-world data are lacking on patients with small-cell lung cancer (SCLC) that has spread, called extensive-stage SCLC (eSCLC), and who have a poor level of functioning, called impair...
- 10 December 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (4) , 443-453
Clinical Effectiveness Outcomes and Healthcare Resource Utilization of Patients Diagnosed with Small-Cell Lung Cancer
Background: Real-world data are lacking on patients with small-cell lung cancer (SCLC) with extensive-stage SCLC (eSCLC) and poor performance status (PS). Patients & methods: Eligible patients diag... Lay abstract Real-world data are lacking on patients with small-cell lung cancer (SCLC) that has spread, called extensive-stage SCLC (eSCLC), and who have a poor level of functioning, called impair...
- 17 November 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (4) , 423-433
Association of Clinico-Genomic Characteristics with Tumor Mutational Burden in Small Cell Lung Cancer Patients
Aim: We evaluated the relationship between clinical and genomic characteristics and tumor mutational burden (TMB) in small cell lung cancer. Materials & methods: In a retrospective analysis of smal... Lay abstract Aim: Lung cancer tumors often have large numbers of mutations in the DNA in their cells – something referred to as a high tumor mutational burden (TMB). We asked whether there was a re...
- 17 November 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (4) , 423-433
Association of Clinico-Genomic Characteristics with Tumor Mutational Burden in Small Cell Lung Cancer Patients
Aim: We evaluated the relationship between clinical and genomic characteristics and tumor mutational burden (TMB) in small cell lung cancer. Materials & methods: In a retrospective analysis of smal... Lay abstract Aim: Lung cancer tumors often have large numbers of mutations in the DNA in their cells – something referred to as a high tumor mutational burden (TMB). We asked whether there was a re...
- Open Access
- 9 July 2020
- Published by Springer Nature in Advances in Therapy
- Vol. 37 (9) , 3746-3760
Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study
Introduction Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)—collectively named inflammatory arthritis (IA). However, the costs associated with switching SC-TNFis are largely unknown. The objective of this retrospective observational study was to explore costs of healthcare resource utilization (HCRU) associated with switching SC-TNFi treatment among biologic-naïve Swedish patients with IA. Methods Using population-based register data, adult patients filling prescriptions between May 6, 2010 and December 31, 2014 for an SC-TNFi (adalimumab, etanercept, certolizumab, and golimumab) were included. Patients switching treatment (cyclers) were matched to treatment persistent patients on the basis of propensity score and follow-up time. HCRU-associated costs were captured and compared 12 months before and 12 months after the index date (defined as the date of the switch). Results A balanced cohort of 594 matched pairs was derived. Prior to the index date, cyclers had significantly higher non-treatment HCRU costs compared to persistent patients ($3815 [3498–4147] vs. $2900; 95%CI [2565–3256]). However, 12 months after the index date, cyclers had significantly increased their non-treatment HCRU costs while persistent patients lowered theirs ($822 [232–1490] vs. $− 313 [− 664–36]). This resulted in a statistically significant difference in difference of $1135 between the groups. Conclusions In biologic-naïve patients treated with SC-TNFi for IA, cyclers significantly increased their non-treatment HCRU costs 12 months after switching treatment while persistent patients lowered their costs during the same time period. As these findings indicate that differences in treatment persistence may have an impact on costs, further research utilizing more comprehensive data sources in alternate settings is warranted.
- 9 July 2020
- Published by Springer Nature in Advances in Therapy
- Vol. 37 (9) , 3746-3760
Open AccessHealthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study
Introduction Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)—collectively named inflammatory arthritis (IA). However, the costs associated with switching SC-TNFis are largely unknown. The objective of this retrospective observational study was to explore costs of healthcare resource utilization (HCRU) associated with switching SC-TNFi treatment among biologic-naïve Swedish patients with IA. Methods Using population-based register data, adult patients filling prescriptions between May 6, 2010 and December 31, 2014 for an SC-TNFi (adalimumab, etanercept, certolizumab, and golimumab) were included. Patients switching treatment (cyclers) were matched to treatment persistent patients on the basis of propensity score and follow-up time. HCRU-associated costs were captured and compared 12 months before and 12 months after the index date (defined as the date of the switch). Results A balanced cohort of 594 matched pairs was derived. Prior to the index date, cyclers had significantly higher non-treatment HCRU costs compared to persistent patients ($3815 [3498–4147] vs. $2900; 95%CI [2565–3256]). However, 12 months after the index date, cyclers had significantly increased their non-treatment HCRU costs while persistent patients lowered theirs ($822 [232–1490] vs. $− 313 [− 664–36]). This resulted in a statistically significant difference in difference of $1135 between the groups. Conclusions In biologic-naïve patients treated with SC-TNFi for IA, cyclers significantly increased their non-treatment HCRU costs 12 months after switching treatment while persistent patients lowered their costs during the same time period. As these findings indicate that differences in treatment persistence may have an impact on costs, further research utilizing more comprehensive data sources in alternate settings is warranted.
- Open Access
- 31 October 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (18) , 7613-7622
Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study
Objectives: The effectiveness and costs of new treatments should be assessed in relation to existing practice. We describe treatments, survival and costs for advanced or metastatic small cell lung cancer (SCLC) patients receiving systemic therapy in the period preceding the introduction of immunotherapies.Materials and Methods: This was a retrospective cohort study of patients aged ≥65 years, identified using linked Surveillance, Epidemiology, and End Results and Medicare databases. Individuals with a new primary diagnosis of SCLC between January 2007 and December 2013 were followed until December 2014. Chemotherapy treatments, health care visits and costs (in 2016 USD), and survival were determined by line of therapy.Results: A total of 11 812 patients were identified with SCLC. First‐line (1L) chemotherapy was received by 6509 (55.1%) patients, most (93.2%) with carboplatin‐ (71.0%) or cisplatin‐ (22.2%) based therapies, typically combined with etoposide (79.2%). Second‐ (2L) and third‐ (3L) line chemotherapies were received by 2238 (18.9%) and 679 (5.7%) patients, of which 48.4% and 30.9%, respectively, were platinum‐based. The median durations of 1L, 2L, and 3L carboplatin‐based therapies were 5.9, 4.8, and 5.4 months, respectively, and the corresponding durations of cisplatin‐based therapies were 5.3, 4.2, and 5.3 months. During 1L, 2L, and 3L chemotherapies, patients averaged 8.2, 7.4, and 7.3 health care visits per month, respectively, and incurred total mean health care costs of $60 223, $42 636, and $35 903 per patient, respectively. Median survival from the start of 1L, 2L, and 3L chemotherapy was 9.2, 6.0, and 5.7 months, respectively.Conclusion: First‐line chemotherapy was primarily platinum‐based, and a plethora of different regimens was used for 2L and 3L chemotherapies. Median survival from the start of 1L chemotherapy was 9 months, with an associated health care cost of $60 000. These data highlight an unmet medical need among SCLC patients receiving systemic therapy.
- 31 October 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (18) , 7613-7622
Open AccessChemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study
Objectives: The effectiveness and costs of new treatments should be assessed in relation to existing practice. We describe treatments, survival and costs for advanced or metastatic small cell lung cancer (SCLC) patients receiving systemic therapy in the period preceding the introduction of immunotherapies.Materials and Methods: This was a retrospective cohort study of patients aged ≥65 years, identified using linked Surveillance, Epidemiology, and End Results and Medicare databases. Individuals with a new primary diagnosis of SCLC between January 2007 and December 2013 were followed until December 2014. Chemotherapy treatments, health care visits and costs (in 2016 USD), and survival were determined by line of therapy.Results: A total of 11 812 patients were identified with SCLC. First‐line (1L) chemotherapy was received by 6509 (55.1%) patients, most (93.2%) with carboplatin‐ (71.0%) or cisplatin‐ (22.2%) based therapies, typically combined with etoposide (79.2%). Second‐ (2L) and third‐ (3L) line chemotherapies were received by 2238 (18.9%) and 679 (5.7%) patients, of which 48.4% and 30.9%, respectively, were platinum‐based. The median durations of 1L, 2L, and 3L carboplatin‐based therapies were 5.9, 4.8, and 5.4 months, respectively, and the corresponding durations of cisplatin‐based therapies were 5.3, 4.2, and 5.3 months. During 1L, 2L, and 3L chemotherapies, patients averaged 8.2, 7.4, and 7.3 health care visits per month, respectively, and incurred total mean health care costs of $60 223, $42 636, and $35 903 per patient, respectively. Median survival from the start of 1L, 2L, and 3L chemotherapy was 9.2, 6.0, and 5.7 months, respectively.Conclusion: First‐line chemotherapy was primarily platinum‐based, and a plethora of different regimens was used for 2L and 3L chemotherapies. Median survival from the start of 1L chemotherapy was 9 months, with an associated health care cost of $60 000. These data highlight an unmet medical need among SCLC patients receiving systemic therapy.
- 14 September 2019
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 21 (1) , 45-54
The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
To estimate the impact of persistence on cost-effectiveness of subcutaneous tumor necrosis factor-α inhibitors (SC-TNFis) from healthcare and societal perspectives in a United Kingdom ankylosing spondylitis (AS) population using a recently published Markov cohort model.
- 14 September 2019
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 21 (1) , 45-54
The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
To estimate the impact of persistence on cost-effectiveness of subcutaneous tumor necrosis factor-α inhibitors (SC-TNFis) from healthcare and societal perspectives in a United Kingdom ankylosing spondylitis (AS) population using a recently published Markov cohort model.